Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pfizer
National Cancer Institute (NCI)
University of Illinois at Chicago
Yale University
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Novartis
Duke University
Tufts Medical Center
National Institutes of Health Clinical Center (CC)